The U.S. Food and Drug Administration approved two new oral antibiotics for gonorrhea: Nuzolvence (zoliflodacin) from Innoviva and Blujepa (gepotidacin) from GSK. Both drugs received expedited designations during review and provide additional therapeutic options as global resistance erodes the efficacy of historical regimens. Regulatory filings indicate the approvals followed pivotal trials demonstrating clinical and microbiological efficacy comparable to standard care. The new agents expand the antibiotic toolbox for Neisseria gonorrhoeae and will prompt guideline updates and stewardship discussions given resistance patterns and treatment sequencing considerations.